The most common side effects of AUSTEDO in people with tardive dyskinesia include inflammation of the nose and throat (nasopharyngitis) and problems sleeping (insomnia). These are not all the …

AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and for the …

2025年8月20日 · Austedo is used to treat the involuntary movements of Huntington's disease and tardive dyskinesia (TD). Includes Austedo side effects, dosage, uses, interactions, and more

2025年11月14日 · Tardive dyskinesia (TD) is a potentially permanent neurologic disorder that is characterized by abnormal, involuntary, and repetitive movements, often impacting the face, tongue, …

2025年11月7日 · AUSTEDO XR and AUSTEDO are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the U.S. Food and Drug Administration in adults for the treatment of tardive …

2025年11月10日 · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to …

VMAT2 inhibitors: There are two FDA-approved drugs to treat tardive dyskinesia, Ingrezza (valbenazine) and Austedo (deutetrabenazine). These medications were approved in 2017 and are known as …

2025年11月7日 · Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of adults with tardive …

6 日前 · Neurocrine Biosciences has announced publication of a narrative review paper on US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitors Ingrezza …

The most common side effects of AUSTEDO in people with tardive dyskinesia include inflammation of the nose and throat (nasopharyngitis) and problems sleeping (insomnia). The most common side …